Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes

27 Apr 2018

Abstract excerpt

Objective: Parkinson’s disease (PD) has significant clinical overlaps with atypical Parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples (n=204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological disorders and treatments
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29755341
DOI: 10.3389/fnagi.2018.00123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesPMID 29755341Read ↗

Differences in Blood and Cerebrospinal Fluid Between Parkinson’s Disease and Related DiseasesSemantic proximity Read ↗

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Semantic proximity Read ↗

Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Semantic proximity Read ↗

Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysisSemantic proximity Read ↗

Parkinson’s Disease: Biomarkers, Treatment, and Risk FactorsSemantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity Read ↗

The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementiaSemantic proximity Read ↗

Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity Read ↗

A proteogenomic view of Parkinson’s disease causality and heterogeneitySemantic proximity Read ↗

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluidSemantic proximity Read ↗

Cerebrospinal Fluid Biomarker Candidates for Parkinsonian DisordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.